News und Analysen
This High-Flying Stock Just Got Some Bad News: Should You Sell?
Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) ended 2023 with an important regulatory approval. The company's gene-editing therapy for a duo of blood-related disorders, Casgevy, earned the nod
Vertex Pharmaceuticals (VRTX) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Vertex Pharmaceuticals (NASDAQ: VRTX)Q4 2023 Earnings CallFeb 05, 2024, 4:30 p.m. ET
Operator
Source Fool.com
Vertex Pharmaceuticals (VRTX) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Vertex Pharmaceuticals (NASDAQ: VRTX)Q4 2023 Earnings CallFeb 05, 2024, 4:30 p.m. ET
Operator
Source Fool.com
Vertex Pharmaceuticals (VRTX) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Vertex Pharmaceuticals (NASDAQ: VRTX)Q4 2023 Earnings CallFeb 05, 2024, 4:30 p.m. ET
Operator
Source Fool.com
Why AbbVie Stock Flew Higher on Monday
Still basking in the afterglow of an encouraging quarterly earnings report, AbbVie (NYSE: ABBV) stock saw a healthy 1.5% rise in price across Monday's trading session. What helped was a series of
EQS-News: MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value
EQS-News: MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value
EQS-Adhoc: Ad hoc: MorphoSys AG Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value and into Purchase Agreement with Incyte for the Sale of Tafasitamab
EQS-Adhoc: Ad hoc: MorphoSys AG Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value and into Purchase Agreement with Incyte for the Sale of Tafasitamab
2 Stocks to Buy Near Their 52-Week Highs
When is it time to buy a stock? One of the best-known pieces of investing advice tells us to buy low and sell high. But what constitutes "low" is relative. A stock near its 52-week high can still be
The Bull Market Left These 3 Stocks Behind, but They're Buys Right Now
With the stock market recently hitting new all-time highs again, times are exciting for people who are fully invested, but these conditions can be more frustrating for those who have cash available
The Bull Market Left These 3 Stocks Behind, but They're Buys Right Now
With the stock market recently hitting new all-time highs again, times are exciting for people who are fully invested, but these conditions can be more frustrating for those who have cash available
2 Healthcare Dividend Kings to Buy and Hold Forever
Dividend Kings are unquestionably among the top picks for income-seeking investors. These are companies that have increased their payouts for at least 50 consecutive years, which strongly suggests
Will UnitedHealth Group Be a Trillion-Dollar Stock by 2030?
UnitedHealth Group (NYSE: UNH) is one of the largest healthcare companies in the world. Its market cap sits at around $470 billion. And this is a stock that has risen tremendously in value. In the
Will UnitedHealth Group Be a Trillion-Dollar Stock by 2030?
UnitedHealth Group (NYSE: UNH) is one of the largest healthcare companies in the world. Its market cap sits at around $470 billion. And this is a stock that has risen tremendously in value. In the
3 Fabulous Dividend Stocks to Buy in February
Any time is a good time to buy solid dividend stocks. But this month is a special time to do so for one simple reason: There's an extra day for investors to buy stocks because it's a leap year.
Social Security Has a Big Immigration Problem -- but It's Probably Not What You Think
A recent survey conducted by the Nationwide Retirement Institute revealed that retirees view inflation and potential Social Security benefit cuts as their biggest concerns. And the Harvard
Could Medtronic Stock Help You Become a Millionaire?
Medical device maker Medtronic (NYSE: MDT) offers investors a couple of ways to build wealth: through the stock's gains and through its dividend income. Over the past decade, the stock has risen by
Is Abbott Laboratories Stock a Buy Now?
Abbott Laboratories (NYSE: ABT) is a diversified health care company that gives investors a great deal of stability. Between testing, nutritional products, pharmaceuticals, and medical devices, the
Better Recovery Story Buy: Novavax vs. Teladoc
Everybody loves a good recovery story. You can get in on a promising company, with a potentially bright future ahead, but at a terrific price. And that means you could win big each time this player
Vertex Pharmaceuticals May Be About to Solve a Common Health Problem. Is the Stock a Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) already brings in billions of dollars annually, thanks to its cystic fibrosis (CF) drugs. The company recently proved it could expand beyond the specialty area
Vertex Pharmaceuticals May Be About to Solve a Common Health Problem. Is the Stock a Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) already brings in billions of dollars annually, thanks to its cystic fibrosis (CF) drugs. The company recently proved it could expand beyond the specialty area
Vertex Pharmaceuticals May Be About to Solve a Common Health Problem. Is the Stock a Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) already brings in billions of dollars annually, thanks to its cystic fibrosis (CF) drugs. The company recently proved it could expand beyond the specialty area
AbbVie (ABBV) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
AbbVie (NYSE: ABBV)Q4 2023 Earnings CallFeb 02, 2024, 9:00 a.m. ET
Operator
Source Fool.com
Cigna Group (CI) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Cigna Group (NYSE: CI)Q4 2023 Earnings CallFeb 02, 2024, 8:30 a.m. ET
Operator
Source Fool.com